keyword
MENU ▼
Read by QxMD icon Read
search

Risedronate

keyword
https://www.readbyqxmd.com/read/29129436/effects-of-teriparatide-and-risedronate-on-new-fractures-in-post-menopausal-women-with-severe-osteoporosis-vero-a-multicentre-double-blind-double-dummy-randomised-controlled-trial
#1
David L Kendler, Fernando Marin, Cristiano A F Zerbini, Luis A Russo, Susan L Greenspan, Vit Zikan, Alicia Bagur, Jorge Malouf-Sierra, Péter Lakatos, Astrid Fahrleitner-Pammer, Eric Lespessailles, Salvatore Minisola, Jean Jacques Body, Piet Geusens, Rüdiger Möricke, Pedro López-Romero
BACKGROUND: No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis. METHODS: In this double-blind, double-dummy trial, we enrolled post-menopausal women with at least two moderate or one severe vertebral fracture and a bone mineral density T score of less than or equal to -1·50. Participants were randomly assigned to receive 20 μg of teriparatide once daily plus oral weekly placebo or 35 mg of oral risedronate once weekly plus daily injections of placebo for 24 months...
November 9, 2017: Lancet
https://www.readbyqxmd.com/read/29094069/third-generation-bisphosphonates-for-cochlear-otosclerosis-stabilizes-sensorineural-hearing-loss-in-long-term-follow-up
#2
Taha A Jan, Aaron K Remenschneider, Christopher Halpin, Margaret Seton, Michael J McKenna, Alicia M Quesnel
Objective: To assess long-term hearing outcomes in patients treated with third-generation bisphosphonates for otosclerosis-related progressive sensorineural hearing loss (SNHL). Study Design: Retrospective case series review. Methods: We performed a retrospective case series review of patients with otosclerosis and progressive SNHL. Patients were treated with either risedronate or zoledronate after a diagnosis of otosclerosis with a significant SNHL component...
October 2017: Laryngoscope Investigative Otolaryngology
https://www.readbyqxmd.com/read/29088987/effect-of-locally-administered-novel-biodegradable-chitosan-based-risedronate-zinc-hydroxyapatite-intra-pocket-dental-film-on-alveolar-bone-density-in-rat-model-of-periodontitis
#3
Deepak Kumar Khajuria, Saadath Fathima Zahra, Rema Razdan
The aim of this study was to develop a chitosan-based risedronate/zinc-hydroxyapatite intrapocket dental film (CRZHDF) for applications in the treatment of alveolar bone loss in an animal model of periodontitis. The physical characteristics (folding endurance, pH, mucoadhesive strength, risedronate content and release) of CRZHDF, exhibited results within the limit. X-ray diffraction analysis indicates reduced or disappeared crystallinity of risedronate and zinc-hydroxyapatite in presence of chitosan. Further, FTIR studies revealed stability of CRZHDF and compatibility between risedronate, zinc-hydroxyapatite and chitosan...
October 31, 2017: Journal of Biomaterials Science. Polymer Edition
https://www.readbyqxmd.com/read/29083977/examining-the-effect-of-medication-adherence-on-risk-of-subsequent-fracture-among-women-with-a-fragility-fracture-in-the-u-s-medicare-population
#4
Allison Keshishian, Natalie Boytsov, Russel Burge, Kelly Krohn, Louise Lombard, Xiang Zhang, Lin Xie, Onur Baser
BACKGROUND: In the United States, osteoporosis affects approximately 10 million people, of whom 80% are women, and it contributes a significant clinical burden to the community. Poor adherence to osteoporosis medications adds to the overall burden of illness. OBJECTIVE: To examine the association of osteoporosis medication adherence and the risk of a subsequent fracture among Medicare-enrolled women with a previous fragility fracture. METHODS: This study was a retrospective observational analysis of U...
November 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29068496/effectiveness-of-oral-bisphosphonates-in-reducing-fracture-risk-among-oral-glucocorticoid-users-three-matched-cohort-analyses
#5
M Amine Amiche, Linda E Lévesque, Tara Gomes, Jonathan D Adachi, Suzanne M Cadarette
The benefit of oral bisphosphonates in reducing fracture risk among in glucocorticoid-induced osteoporosis is controversial. We aimed to estimate the effectiveness of oral bisphosphonates in reducing fracture risk in a cohort of new chronic oral glucocorticoid users. We created three matched cohorts using healthcare administrative data from Ontario, Canada. We included residents aged 66 years and older initiating chronic oral glucocorticoids (≥450 mg prednisone equivalent and ≥ 2 GC prescriptions within a 6-month window) between January 1998 and September 2014...
October 25, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29063697/erythema-multiforme-like-eruption-induced-by-risedronate
#6
Leonardo Bianchi, Katharina Hansel, Paolo Romita, Caterina Foti, Luca Stingeni
No abstract text is available yet for this article.
November 2017: Contact Dermatitis
https://www.readbyqxmd.com/read/29045447/protective-effect-of-low-dose-risedronate-against-osteocyte-apoptosis-and-bone-loss-in-ovariectomized-rats
#7
Tingjun Ye, Peng Cao, Jin Qi, Qi Zhou, D Sudhaker Rao, Shijing Qiu
Osteocyte apoptosis is the first reaction to estrogen depletion, thereby stimulating osteoclastic bone resorption resulting in bone loss. We investigated the effects of two different risedronate (RIS) doses (high and low) on osteocyte apoptosis, osteoclast activity and bone loss in ovariectomized rats. Forty rats with ovariectomy (OVX) and sham ovariectomy (SHAM) were divided into 4 groups: 1) SHAM rats treated with saline (SHAM); 2) OVX rats treated with saline (OVX); 3) OVX rats treated with low-dose RIS (OVX-LR, 0...
2017: PloS One
https://www.readbyqxmd.com/read/29036218/crystallographic-and-thermodynamic-characterization-of-phenylaminopyridine-bisphosphonates-binding-to-human-farnesyl-pyrophosphate-synthase
#8
Jaeok Park, Dmitry Rodionov, Joris W De Schutter, Yih-Shyan Lin, Youla S Tsantrizos, Albert M Berghuis
Human farnesyl pyrophosphate synthase (hFPPS) catalyzes the production of the 15-carbon isoprenoid farnesyl pyrophosphate. The enzyme is a key regulator of the mevalonate pathway and a well-established drug target. Notably, it was elucidated as the molecular target of nitrogen-containing bisphosphonates, a class of drugs that have been widely successful against bone resorption disorders. More recently, research has focused on the anticancer effects of these inhibitors. In order to achieve increased non-skeletal tissue exposure, we created phenylaminopyridine bisphosphonates (PNP-BPs) that have bulky hydrophobic side chains through a structure-based approach...
2017: PloS One
https://www.readbyqxmd.com/read/28992488/hydroxyapatite-functionalization-to-trigger-adsorption-and-release-of-risedronate
#9
Lucia Forte, Stéphanie Sarda, Christèle Combes, Fabien Brouillet, Massimo Gazzano, Olivier Marsan, Elisa Boanini, Adriana Bigi
Bisphosphonates are widely employed drugs for the treatment of pathologies characterized by excessive bone resorption, and display a great affinity for apatitic supports. In this work we investigate how hydroxyapatite functionalization can influence the processes of adsorption and release of a bisphosphonate, namely risedronate. To this aim, pure hydroxyapatite (HA), hydroxyapatite with a partial substitution of Zn to Ca (ZnHA) and poly-ethylenimine-functionalized hydroxyapatite (HAPEI) were submitted to interaction with risedronate solution...
September 28, 2017: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/28955236/improvement-of-bone-physiology-and-life-quality-due-to-association-of-risedronate-and-anastrozole
#10
Vincenzo Monda, Gelsy A Lupoli, Giovanni Messina, Rosario Peluso, Annalisa Panico, Ines Villano, Monica Salerno, Francesco Sessa, Francesca Marciello, Fiorenzo Moscatelli, Anna Valenzano, Leonardo Molino, Roberta Lupoli, Francesco Fonderico, Anna Tortora, Agata Pisano, Maria Ruberto, Marsala Gabriella, Gina Cavaliere, Giovanna Trinchese, Maria P Mollica, Luigi Cipolloni, Giuseppe Cibelli, Marcellino Monda, Giovanni Lupoli, Antonietta Messina
The endocrine therapy is the new frontiers of many breast cancers hormone sensitive. Hormone therapy for treating women with hormone receptor-positive cancer suppresses breast cancer growth either by reducing estrogen synthesis or by interfering with the action of estrogen within tumor cells. In this prospective randomized observational study we investigate the effect of adjuvant anastrozole in monotherapy or associated with risedronate on bone physiology and quality of life in postmenopausal, hormone-sensitive early breast cancer women at mild to moderate risk of fragility fractures...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28940569/weekly-oral-bisphosphonates-over-2%C3%A2-years-prevent-bone-loss-in-cardiac-transplant-patients
#11
Uwe Lange, Katharina Classen, Ulf Müller-Ladner, Manfred Richter
BACKGROUND: Heart transplantation (HTX) is an established therapy for end-stage heart disease. The aim of this study was to determine whether application of oral bisphosphonates is effective in preventing osseous complications after HTX. METHODS: Thirty-three cardiac transplant recipients were treated with alendronate 70 mg/wk or risedronate 35 mg/wk in combination with 1000 mg calcium and 800 IU vitamin D. Markers of bone metabolism and dual-energy X-ray absorptiometry (DXA) were determined directly after HTX and 2 years later...
September 23, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/28937990/treatment-of-opg-deficient-mice-with-wp9qy-a-rankl-binding-peptide-recovers-alveolar-bone-loss-by-suppressing-osteoclastogenesis-and-enhancing-osteoblastogenesis
#12
Yuki Ozaki, Masanori Koide, Yuriko Furuya, Tadashi Ninomiya, Hisataka Yasuda, Midori Nakamura, Yasuhiro Kobayashi, Naoyuki Takahashi, Nobuo Yoshinari, Nobuyuki Udagawa
Osteoblasts express two key molecules for osteoclast differentiation, receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG), a soluble decoy receptor for RANKL. RANKL induces osteoclastogenesis, while OPG inhibits it by blocking the binding of RANKL to RANK, a cellular receptor of RANKL. OPG-deficient (OPG-/-) mice exhibit severe alveolar bone loss with enhanced bone resorption. WP9QY (W9) peptide binds to RANKL and blocks RANKL-induced osteoclastogenesis. W9 is also reported to stimulate bone formation in vivo...
2017: PloS One
https://www.readbyqxmd.com/read/28936581/exploring-methods-for-comparing-the-real-world-effectiveness-of-treatments-for-osteoporosis-adjusted-direct-comparisons-versus-using-patients-as-their-own-control
#13
Linda Karlsson, Johan Mesterton, Maurille Feudjo Tepie, Michele Intorcia, Jetty Overbeek, Oskar Ström
Using Swedish and Dutch registry data for women initiating bisphosphonates, we evaluated two methods of comparing the real-world effectiveness of osteoporosis treatments that attempt to adjust for differences in patient baseline characteristics. Each method has advantages and disadvantages; both are potential complements to clinical trial analyses. PURPOSE: We evaluated methods of comparing the real-world effectiveness of osteoporosis treatments that attempt to adjust for both observed and unobserved confounding...
September 21, 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28921820/systematic-review-and-network-meta-analysis-on-the-relative-efficacy-of-osteoporotic-medications-men-with-prostate-cancer-on-continuous-androgen-deprivation-therapy%C3%A2-to-reduce-risk-of-fragility-fractures
#14
REVIEW
Yeesha Poon, Petros Pechlivanoglou, Shabbir M H Alibhai, David Naimark, Jeffrey S Hoch, Emmanuel Papadimitropoulos, Mary-Ellen Hogan, Murray Krahn
BACKGROUND: Androgen deprivation therapy (ADT) is an effective treatment for men with advanced prostate cancer, but loss of bone mineral density (BMD) is a major risk factor for fractures. This analysis evaluated the relative effectiveness of osteoporosis treatments using BMD as a surrogate endpoint for fragility fractures in men on continuous ADT. METHOD: We included randomized controlled trials studying bisphosphonates, denosumab, toremifene, and raloxifene in patients with non-metastatic prostate cancer on ADT for review...
September 18, 2017: BJU International
https://www.readbyqxmd.com/read/28875236/bisphosphonate-drug-holidays-in-postmenopausal-osteoporosis-effect-on-clinical-fracture-risk
#15
M A Mignot, N Taisne, I Legroux, B Cortet, J Paccou
A cohort of 183 postmenopausal women, who had either discontinued or continued bisphosphonates (BPs) after first-line therapy, was used to investigate the relationships between "drug holiday" and clinical fracture. The risk of new clinical fractures was found to be 40% higher in women who had taken a BP "drug holiday." INTRODUCTION: BPs are the most widely used treatment for postmenopausal osteoporosis. The optimal treatment duration, however, remains unclear. The purpose of this study was to evaluate the fracture risk in postmenopausal women with osteoporosis after discontinuing BP treatment (BP "drug holiday")...
December 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28866852/clinical-and-biochemical-response-to-neridronate-treatment-in-a-patient-with-osteoporosis-pseudoglioma-syndrome-oppg
#16
M Celli, P D'Eufemia, P Persiani, A Turchetti, A Febbo, Y D'Alfonso, L Celli, A Zambrano
Osteoporosis-pseudoglioma syndrome (OPPG) is a rare autosomal recessive syndrome characterized by juvenile-onset osteoporosis and ocular abnormalities due to a low-density lipoprotein receptor-related protein 5 (LRP5) gene mutation. Treatment with bisphosphonates, particularly with pamidronate and risedronate, has been reported to be of some efficacy in this condition. We report on a patient with OPPG due to an LRP5 gene mutation, who showed an encouraging response after a 36-month period of neridronate therapy...
November 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28860420/baseline-mineralizing-surface-determines-the-magnitude-of-the-bisphosphonate-effect-on-cortical-bone-mineralization-in-postmenopausal-osteoporotic-patients
#17
B M Misof, S Blouin, S Lueger, E P Paschalis, R R Recker, R Phipps, K Klaushofer, P Roschger
PURPOSE: To determine the effect of short- or long-term bisphosphonate treatment on cortical bone mineralization density distribution (BMDD). METHODS: BMDD was assessed by quantitative backscatter electron imaging in postmenopausal osteoporosis: in paired transiliac biopsy samples (n=36) at baseline and after 3 years risedronate treatment from a clinical study, in transiliac biopsy samples from patients who were treated with either risedronate (n=31) or alendronate (n=68) for 3 to 7 years from an observational study...
September 1, 2017: Journal of Musculoskeletal & Neuronal Interactions
https://www.readbyqxmd.com/read/28808351/inhibition-of-the-mevalonate-pathway-augments-the-activity-of-pitavastatin-against-ovarian-cancer-cells
#18
Marwan Ibrahim Abdullah, Mohammed Najim Abed, Alan Richardson
Only 40% of patients with advanced ovarian cancer survive more than 5 years. We have previously shown that pitavastatin induces regression of ovarian cancer xenografts in mice. To evaluate whether the response of ovarian cancer cells to pitavastatin is potentiated by farnesyl diphosphate synthase inhibitors or geranylgeraniol transferase I inhibitors, we evaluated combinations of pitavastatin with zoledronic acid, risedronate and GGTI-2133 in a panel of ovarian cancer cells. Pitavastatin (IC50 = 0.6-14 μM), zoledronic acid (IC50 = 21-57 μM), risedronate (IC50 > 100 μM) or GGTI-2133 (IC50 > 25 μM) inhibited the growth of ovarian cancer cell cultures...
August 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28721134/osteoporosis-in-men
#19
REVIEW
Waldemar Misiorowski
Osteoporotic fractures are the leading cause of morbidity and mortality among aging men. 30% of all hip fractures occur in men, and mortality resulting from not only the hip fracture, but also the spine and other major osteoporotic fractures, is significantly higher in men than in women. As in women, hypogonadism is the best documented risk factor for developing osteoporosis in men. In older men, testosterone levels are negatively correlated with the risk of fractures, and it seems that this age-related testosterone deficiency should not be considered as one of the many causes of secondary osteoporosis, rather one of the major and most important mechanisms of senile osteoporosis...
June 2017: Przeglad Menopauzalny, Menopause Review
https://www.readbyqxmd.com/read/28713001/comparison-of-the-properties-of-implantable-matrices-prepared-from-degradable-and-non-degradable-polymers-for-bisphosphonate-delivery
#20
Tamás Sovány, Anna Csüllög, Ernő Benkő, Géza Regdon, Klára Pintye-Hódi
The aim of the present study was the development of directly compressed tablets for implantable delivery of risedronate sodium for osteoporosis treatment and the comparison of the mechanism and kinetics of drug release from biogradable (chitosan) and non-degradable (PVC) polymer matrices. The compositions and process parameters were optimized in accordance to a mixed 2 and 3 level full factorial design. Critical Quality Attributes (CQA), such as diametral breaking hardness, porosity and speed of drug dissolution were investigated...
November 30, 2017: International Journal of Pharmaceutics
keyword
keyword
27345
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"